Post-earnings recap
Reported
Mon, Aug 10, 2026
EPS actual
$-0.99
EPS est.
$-0.98
EPS surprise
-0.51%
1-day move
+3.83%
Axsome Therapeutics reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock reacted positively, increasing by 3.83%. This could indicate that investors are looking beyond the EPS miss, possibly focusing on other aspects of the company's performance or future potential.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.99 | $-0.84 | -0.51% |
| Revenue | — | $222M | — |
No transcript is on record for the earnings call, so the analysis is based solely on the numerical results.
Axsome Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for central nervous system disorders. With a market cap of $11 billion, its advancements in this sector are crucial as they address significant unmet medical needs.
Last quarter
In Q1-2026, Axsome reported an EPS of -$1.26, which was worse than the expected -$0.85, leading to a significant stock reaction. The stock rose 8.31% the following day, indicating some investor optimism despite the miss.
EPS beat streak
0Q
EPS beat rate
50%
Avg EPS surprise
-12.53%
Avg 1-day reaction
+2.76%
Analysts are expecting a challenging quarter with a consensus EPS of -$0.84 and revenue of $222 million. The market is closely watching for any signs of improvement in financial performance.
Bull case
If Axsome can exceed revenue expectations and narrow its losses, it could signal a turnaround, boosting investor confidence and stock price.
Bear case
Continued losses and failure to meet revenue targets could raise concerns about the company's viability and lead to a negative market reaction.
Key metrics to watch
EPS
-$0.84Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
$222MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Axsome's revenue meet or exceed the consensus estimate of $222 million?
Revenue performance is critical for assessing the company's growth trajectory and market demand for its products.
Q2
Can Axsome narrow its EPS loss to meet or beat the consensus of -$0.84?
A smaller loss could indicate operational improvements and boost investor confidence.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±5.7%
Why consensus could be wrong
The consensus may be overly pessimistic about Axsome's ability to improve its financial metrics this quarter, particularly given the potential for new product uptake.
Supporting evidence
Options are pricing a 19.2% move, indicating higher volatility expectations than historical averages.
The company has previously shown resilience, with positive stock reactions following earnings surprises.
Recent developments in product pipeline could lead to unexpected revenue boosts.
Key risk
If revenue exceeds $222 million, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is evaluating whether Axsome can show signs of recovery after recent earnings misses.
Bull confirmed if
Achieving revenue above $222 million and an EPS loss narrower than -$0.84 would confirm a positive outlook.
Bear confirmed if
An EPS loss greater than -$0.84 and revenue below $200 million would signal ongoing challenges.
What the market is pricing for the move.
Implied Move
±19.2%
Historical Avg
±4.6%
The options market is pricing in a significant potential movement in the stock, reflecting uncertainty around the earnings report.
Options are pricing ±19.2% while AXSM has averaged ±4.6% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
48.8%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
74.59%
of float
Insider
15.08%
of float
Holders
661
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
3,103,708 sh · $536.8M
5.93%
-20.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Axsome beats expectations, history suggests a potential stock increase of around 2.93%, confirming a positive turnaround narrative.
In line / cautious
If results are in line with expectations, the stock may react moderately, reflecting cautious investor sentiment.
Miss
A miss could lead to a decline, with historical data suggesting an average drop of 1.28% following such outcomes.
The lines on the call that would change the story.
Vanguard Portfolio Management LLC
1,983,514 sh · $343.1M
3.79%
-3.6%
Vanguard Capital Management LLC
1,965,086 sh · $339.9M
3.75%
1.4%
Invesco Ltd.
1,671,684 sh · $289.2M
3.19%
28.8%
FMR, LLC
1,539,163 sh · $266.2M
2.94%
-1.8%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.